There is a significant unmet medical need for patients with Major Depressive Disorder (MDD) who either do not respond to, or do not tolerate, current augmentation approaches for treatment.
For this Phase II study of an oral investigative compound, Science 37® embarked on a journey to design the first ever decentralized clinical trial (DCT) in depression. Each DCT execution brings a unique set of challenges and, therefore, demands a unique set of solutions. The aim was to remove geographical barriers, enable universal access to patients and providers, increase diversity, reduce the burden of participation and, consequently, keep more patients in the study.
This research poster was presented at the recent CNS Summit 2021 by Dr. Christopher Reist.